Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbhfiledCriticalImmatics Biotechnologies Gmbh
Publication of AR114736A1publicationCriticalpatent/AR114736A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
La presente se refiere a péptidos, proteínas, ácidos nucleicos y células destinados a la utilización en métodos inmunoterapéuticos. En particular, la presente se refiere a la inmunoterapia contra el cáncer. La presente se refiere asimismo a epítopos peptídicos para linfocitos T asociados a tumores, solos o en combinación con otros péptidos asociados a tumores que, por ejemplo, pueden servir como principios activos farmacéuticos en composiciones vacunales destinadas a estimular respuestas inmunitarias antitumorales, o a estimular ex vivo linfocitos T que después serán transferidos a los pacientes. Los péptidos unidos a moléculas del complejo mayor de histocompatibilidad (MHC), o los péptidos como tales, también pueden ser dianas de anticuerpos, de receptores de linfocitos T solubles, y de otras moléculas de unión.This refers to peptides, proteins, nucleic acids, and cells for use in immunotherapeutic methods. In particular, this is concerned with immunotherapy against cancer. The present also refers to peptide epitopes for tumor-associated T lymphocytes, alone or in combination with other tumor-associated peptides that, for example, can serve as active pharmaceutical ingredients in vaccine compositions intended to stimulate antitumor immune responses, or to stimulate ex vivo. T lymphocytes that will later be transferred to patients. Peptides bound to major histocompatibility complex (MHC) molecules, or peptides as such, can also be targets of antibodies, soluble T cell receptors, and other binding molecules.
ARP190102637A2018-09-172019-09-16
PEPTIDES RESTRICTED BY B * 44 FOR USE IN IMMUNOTHERAPY AGAINST CANCER AND RELATED METHODS
AR114736A1
(en)
Novel peptides and novel peptide combinations as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma, as well as other types of cancer (divisional application no. 201803293)
Peptides and peptide combinations for use in immunotherapy against small cell lung cancer and other types of cancer (divisional application no. 201800780)
New peptides (seq id no: 146) and new peptide combinations for use in immunotherapy against non-Hodgkin's lymphoma (NHL) and other cancers (divisional application no. 201802096)